Advertisement

Topics

FDA Approval Sought for Frontline Venetoclax Combo in AML

12:42 EDT 12 Jul 2018 | OncLive

A supplemental New Drug Application has been submitted to the FDA for venetoclax (Venclexta) for use in combination with a hypomethylating agent or low-dose cytarabine for the first-line treatment of patients with acute myeloid leukemia

Original Article: FDA Approval Sought for Frontline Venetoclax Combo in AML

NEXT ARTICLE

More From BioPortfolio on "FDA Approval Sought for Frontline Venetoclax Combo in AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...